ClinicalTrials.gg
TerminatedNCT02540330007Updated Apr 3, 2024Results posted

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

A Phase 2 interventional study of Fulvestrant in Female Breast Carcinoma and Female Ductal Carcinoma In Situ, sponsored by Atossa Therapeutics, Inc.. Terminated at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's listed conditions name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision (See Detailed Description)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Enrollment
157th of 171
3 · median 51
Started
2016
with 7 others
Phase 2
60 of 210
9 open now
Registered
127th of 210
by date

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 157th largest by enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2016, is one of 60 in phase 2, and was the 127th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS. The first subject of each of five groups will receive fulvestrant intramuscularly. The subsequent 5 subjects of each group will receive fulvestrant by intraductal instillation. All subjects will be monitored for systemic and local adverse events during the procedure, and following the procedure until mastectomy or lumpectomy. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

Read the detailed description

This is an open-label, non-randomized pharmacokinetic study of pre-surgical fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified upon admission to the institution for surgical management of breast cancer or DCIS, specifically mastectomy or lumpectomy. There will be 5 groups, each consisting of 6 subjects. The first subject of each group will receive fulvestrant administered intramuscularly and the next 5 subjects will receive fulvestrant intraductally. Subjects where at least 1 suitable duct is identified may undergo nipple aspiration in order to facilitate duct identification and intraductal infusion of a fulvestrant accompanied by imaging (saline+ ultrasound). A maximum of 5 ducts will receive intraductal infusion of fulvestrant. Across all ducts, the total dose will not exceed 500 mg (10 mL). All subjects will be monitored for systemic and local adverse events during the procedure, immediately following the procedure, within 30 minutes, 1 hour, 4 hours and by phone following discharge on Days +1 and +2, +7, and pre-operative. Subsequent to mastectomy or lumpectomy, subjects will be assessed for systemic adverse events until discharge. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

This study was terminated due to revised commercial analyses including a review of the potential to enroll in a timely manner the planned number of patients. This study was not terminated because of safety or efficacy concerns.

03

Conditions studied

  • Female Breast Carcinoma
  • Female Ductal Carcinoma In Situ

Browse trials for

04

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's enrollment of 3 is below the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female
  2. 18 years of age or older
  3. Scheduled to undergo non-nipple sparing mastectomy for Invasive Breast Cancer or DCIS
  4. Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy or lumpectomy
  5. Estrogen Receptor-positive pathology
  6. performance scale of 0-1
  7. Adequate organ function as defined by the following criteria:

    • (ANC) ≥ 1500/μl
    • ≥ 100,000/μl
    • ≥ 9.0 g/dl
    • Creatinine ≤ 2 times
    • ≤ 2 times upper limit of normal
    • Transaminases (/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of normal
  8. Able to sign
  9. Willing to use effective for at least 100 days post study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent treatment with another anti-estrogen
  2. Presence of an active infection requiring systemic therapy
  3. The following conditions contra-indicating fulvestrant administration:

    1. Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant use (excluding aspirin and anti-inflammatories)
    2. Subjects with a known to fulvestrant or any of its formulation components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate.
    3. Severe hepatic impairment.
  4. Prior surgery on the ipsilateral breast which interrupts communication of the ductal systems with the nipple
  5. Prior radiation to the breast
  6. Pregnant or lactating
  7. Impaired cardiac function or history of cardiac problems of Class 111 and IV
  8. Poor nutritional state as indicated by a below 20.
  9. Presence of serious infection not controlled with systemic therapy
  10. History of allergies to Lidocaine or Novocain
  11. Concurrent participation in an experimental drug study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Intramuscular Fulvestrant

    500mg fulvestrant administered intramuscularly

    Drug: Fulvestrant

  • Experimental
    Intraductal Fulvestrant

    up to 500mg fulvestrant administered intraductally

    Drug: Fulvestrant

Interventions

07

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Two Delivery Methods

    Number of adverse events per CTCAE v4.0 after treatment with fulvestrant by route of administration

    Time frame: Up to 4 weeks

08

Results

Posted Apr 5, 2022

Participant flow

Participant flow — Overall Study
MilestoneIntramuscular FulvestrantIntraductal Fulvestrant
Started21
Completed21
Not completed00

Outcome measures

PrimarySafety and Tolerability of Two Delivery Methods

Number of adverse events per CTCAE v4.0 after treatment with fulvestrant by route of administration

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Safety and Tolerability of Two Delivery Methods
ParticipantsIntramuscular RouteIntraductal Route
Safety and Tolerability of Two Delivery Methods10

Adverse events

Collected over Up to 50 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intramuscular Fulvestrant0/2 (0%)0/2 (0%)1/2 (50%)
Intraductal Fulvestrant0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent other events
Most frequent other events
EventIntramuscular FulvestrantIntraductal Fulvestrant
PainMusculoskeletal and connective tissue disorders1/20/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intramuscular FulvestrantIntraductal FulvestrantTotal
Mean67 (59 to 75)45 (45 to 45)60 (45 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Intramuscular FulvestrantIntraductal FulvestrantTotal
Female213
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intramuscular FulvestrantIntraductal FulvestrantTotal
Hispanic or Latino011
Not Hispanic or Latino202
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intramuscular FulvestrantIntraductal FulvestrantTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White000
More than one race000
Unknown or Not Reported011
09

Study locations

3 sites
  • The Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Aug 2020, 53 months.

Results were first posted in Apr 2022, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2015
First posted
Sep 3, 2015
StartActual
Mar 2016
Primary completionActual
Aug 13, 2020
CompletionActual
Aug 13, 2020
Results first posted
Apr 5, 2022
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02540330
Lead sponsor
Atossa Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2015
Start date
Mar 2016
Primary completion
Aug 13, 2020
Completion
Aug 13, 2020
Results posted
Apr 5, 2022
Last update
Apr 3, 2024

Study contacts

Steven C Quay
study chair · Atossa Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion